A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients

Keita Matsubara, Miyuki Morozumi, Takafumi Okada, Takahiro Matsushima, Osamu Komiyama, Michi Shoji, Takashi Ebihara, Kimiko Ubukata, Yoshitake Sato, Hironobu Akita, Keisuke Sunakawa, Satoshi Iwata

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1%) were classified as MS-M. pneumoniae and 30 (31.9%) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5% for MS-M. pneumoniae and 22.7% for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.

Original languageEnglish
Pages (from-to)380-383
Number of pages4
JournalJournal of Infection and Chemotherapy
Volume15
Issue number6
DOIs
Publication statusPublished - 2009 Dec
Externally publishedYes

Fingerprint

Mycoplasma pneumoniae
Macrolides
Pediatrics
Infection
Clinical Studies
Clinical Laboratory Techniques
Microbial Sensitivity Tests
Anti-Infective Agents
Age of Onset

Keywords

  • Child
  • Drug resistance
  • Macrolide
  • Mycoplasma pneumoniae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. / Matsubara, Keita; Morozumi, Miyuki; Okada, Takafumi; Matsushima, Takahiro; Komiyama, Osamu; Shoji, Michi; Ebihara, Takashi; Ubukata, Kimiko; Sato, Yoshitake; Akita, Hironobu; Sunakawa, Keisuke; Iwata, Satoshi.

In: Journal of Infection and Chemotherapy, Vol. 15, No. 6, 12.2009, p. 380-383.

Research output: Contribution to journalArticle

Matsubara, K, Morozumi, M, Okada, T, Matsushima, T, Komiyama, O, Shoji, M, Ebihara, T, Ubukata, K, Sato, Y, Akita, H, Sunakawa, K & Iwata, S 2009, 'A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients', Journal of Infection and Chemotherapy, vol. 15, no. 6, pp. 380-383. https://doi.org/10.1007/s10156-009-0715-7
Matsubara, Keita ; Morozumi, Miyuki ; Okada, Takafumi ; Matsushima, Takahiro ; Komiyama, Osamu ; Shoji, Michi ; Ebihara, Takashi ; Ubukata, Kimiko ; Sato, Yoshitake ; Akita, Hironobu ; Sunakawa, Keisuke ; Iwata, Satoshi. / A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. In: Journal of Infection and Chemotherapy. 2009 ; Vol. 15, No. 6. pp. 380-383.
@article{d434bad5e9e84f0b8d7a526f0c25ab5a,
title = "A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients",
abstract = "In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1{\%}) were classified as MS-M. pneumoniae and 30 (31.9{\%}) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5{\%} for MS-M. pneumoniae and 22.7{\%} for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.",
keywords = "Child, Drug resistance, Macrolide, Mycoplasma pneumoniae",
author = "Keita Matsubara and Miyuki Morozumi and Takafumi Okada and Takahiro Matsushima and Osamu Komiyama and Michi Shoji and Takashi Ebihara and Kimiko Ubukata and Yoshitake Sato and Hironobu Akita and Keisuke Sunakawa and Satoshi Iwata",
year = "2009",
month = "12",
doi = "10.1007/s10156-009-0715-7",
language = "English",
volume = "15",
pages = "380--383",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients

AU - Matsubara, Keita

AU - Morozumi, Miyuki

AU - Okada, Takafumi

AU - Matsushima, Takahiro

AU - Komiyama, Osamu

AU - Shoji, Michi

AU - Ebihara, Takashi

AU - Ubukata, Kimiko

AU - Sato, Yoshitake

AU - Akita, Hironobu

AU - Sunakawa, Keisuke

AU - Iwata, Satoshi

PY - 2009/12

Y1 - 2009/12

N2 - In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1%) were classified as MS-M. pneumoniae and 30 (31.9%) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5% for MS-M. pneumoniae and 22.7% for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.

AB - In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1%) were classified as MS-M. pneumoniae and 30 (31.9%) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5% for MS-M. pneumoniae and 22.7% for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.

KW - Child

KW - Drug resistance

KW - Macrolide

KW - Mycoplasma pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=76749125394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749125394&partnerID=8YFLogxK

U2 - 10.1007/s10156-009-0715-7

DO - 10.1007/s10156-009-0715-7

M3 - Article

VL - 15

SP - 380

EP - 383

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 6

ER -